AnteoTech Ltd (ASX: ADO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Anteotech Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $492.60 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.97 billion
Earnings per share -0.004
Dividend per share N/A
Year To Date Return 138.10%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

AnteoTech Ltd (ASX: ADO)
Latest News

ADO ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AnteoTech Ltd

AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its keys areas are Energy and Life ScienceDivision. The company is developing four products named AnteoCoat, AnteoX, AnteoBind, and AnteoRelease, all of these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the Anteo Intellectual property.

ADO Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
27 Oct 2021 $0.25 $0.00 0.00% 2,374,796 $0.26 $0.27 $0.25
26 Oct 2021 $0.25 $0.00 0.00% 3,579,577 $0.25 $0.27 $0.25
25 Oct 2021 $0.25 $0.00 0.00% 1,110,406 $0.25 $0.26 $0.25
22 Oct 2021 $0.25 $0.01 4.08% 2,021,287 $0.25 $0.25 $0.24
21 Oct 2021 $0.25 $0.00 0.00% 1,129,113 $0.25 $0.25 $0.24
20 Oct 2021 $0.25 $0.00 0.00% 2,824,672 $0.25 $0.25 $0.24
19 Oct 2021 $0.25 $0.02 8.89% 3,212,239 $0.24 $0.25 $0.24
18 Oct 2021 $0.23 $-0.01 -4.35% 2,766,578 $0.24 $0.24 $0.23
15 Oct 2021 $0.23 $0.00 0.00% 1,942,692 $0.24 $0.24 $0.23
14 Oct 2021 $0.24 $0.00 0.00% 1,889,305 $0.23 $0.24 $0.23
13 Oct 2021 $0.24 $0.02 9.30% 3,589,104 $0.22 $0.24 $0.22
12 Oct 2021 $0.22 $-0.01 -4.44% 2,331,655 $0.23 $0.23 $0.21
11 Oct 2021 $0.23 $-0.01 -4.35% 1,985,033 $0.24 $0.24 $0.22
08 Oct 2021 $0.23 $0.01 4.44% 2,569,005 $0.23 $0.24 $0.23
07 Oct 2021 $0.23 $0.01 4.55% 2,213,841 $0.22 $0.24 $0.22
06 Oct 2021 $0.22 $-0.01 -4.44% 3,469,795 $0.23 $0.24 $0.22
05 Oct 2021 $0.23 $-0.02 -8.16% 4,880,059 $0.24 $0.24 $0.22
04 Oct 2021 $0.25 $-0.02 -7.55% 4,695,764 $0.27 $0.27 $0.24
01 Oct 2021 $0.27 $0.00 0.00% 4,077,534 $0.27 $0.27 $0.26
30 Sep 2021 $0.27 $-0.01 -3.64% 3,410,702 $0.27 $0.28 $0.27
29 Sep 2021 $0.28 $0.01 3.70% 4,410,521 $0.27 $0.28 $0.26
28 Sep 2021 $0.27 $-0.01 -3.64% 5,187,545 $0.28 $0.28 $0.27

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
17 Sep 2021 Glenda McLoughlin Buy 250 $58,750
On-market trade.
02 Aug 2021 Geoffrey Cumming Sell 500 $112,500
On-market trade.
25 May 2021 Christopher Parker Sell 17 $4,515
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 Christopher Parker Buy 17 $4,515
Participation in share purchase plan.
25 May 2021 Geoffrey Cumming Sell 17 $4,515
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 Geoffrey Cumming Buy 17 $4,515
Participation in share purchase plan.
25 May 2021 John (Jack) Hamilton Sell 24 $6,257
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 John (Jack) Hamilton Buy 24 $6,257
Participation in share purchase plan.
27 Nov 2020 Geoffrey Cumming Sell 1 $128,901
On-market trade.
23 Nov 2020 Matthew (Matt) Sanderson Buy 2 $52,569
Exercise of options.
23 Nov 2020 Matthew (Matt) Sanderson Exercise 2 $52,569
Exercise of options.
16 Nov 2020 John (Jack) Hamilton Issued 2 $216,000
Issue of options.
16 Nov 2020 John (Jack) Hamilton Exercise 5 $117,736
Exercise of options.
16 Nov 2020 John (Jack) Hamilton Issued 5 $117,736
Exercise of options.
12 Nov 2020 Geoffrey Cumming Issued 1 $127,500
Issue of options.
12 Nov 2020 Matthew (Matt) Sanderson Issued 1 $127,500
Issue of options.
12 Nov 2020 Christopher Parker Issued 1 $127,500
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Katherine Leslie Woodthorpe Non-Executive Director Sep 2021
Dr Woodthorpe is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a range of organizations including listed entities, government boards and for purpose organizations. She has experience working in a range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. Katherine also has knowledge of the private equity and venture capital industries in the financial sector as well as working closely with superannuation funds on their alternative investments in the private equity space. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a range of management and board positions, in Australia and overseas. Katherine commenced her career initially as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988. Dr Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd and Vast Solar Pty Ltd.
Dr Geoffrey James Cumming Non-Executive Director Apr 2009
Dr Cumming has over 20 years experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roches global organisation. He was also Managing Director and CEO of an Australian based biotechnology company commercialising a range of products in cancer diagnosis and treatment. During his tenure he was responsible for taking research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Geoffrey is a Non-Executive Director of Multiple Sclerosis Research Australia, a not-for profit organisation.
Dr John (Jack) Andrew Hamilton Non-Executive ChairmanNon-Executive Director Apr 2018
Dr Hamilton's career spans over 30 years in the energy sector. He has held senior positions across the energy sector over the past 15 years including heading up Australia's largest resource project as Director North West Shelf Ventures for Woodside Energy Ltd, CEO for a Liquid Natural Gas project in PNG following on from a 21 year career with Shell in both local and international roles. His career gained experience across a range of functions including, strategy development, commercial marketing, mergers/acquisitions, capital raisings, manufacturing operations and project management in the energy and petrochemical sectors. Jack is currently a Non-Executive Director with Calix Ltd. He formerly held directorships with DUET Group Ltd, Southern Cross Electrical Engineering Ltd, Federation Training and chair of Renu Energy Ltd and Antilles Oil and Gas NL. He is member of the Risk Committee.
Ms Glenda McLoughlin Non-Executive Director Sep 2021
Ms McLaughlin is an experienced Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas company Metgasco Ltd, where she was Executive Director and Chief Financial Officer for eight years. Ms McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands. Ms McLoughlin will also Chair of AnteoTech's Risk Committee.
Mr Richard Shubrick Martin Non-Executive Director Sep 2005
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
Mr Christopher Parker Non-Executive Director Apr 2019
Mr Parker has over 30 years of experience in both domestic and international life sciences sectors predominately through a career with Roche Diagnostics, an internationally renowned pharmaceutical and diagnostics company. In his final role with Roche, before retiring in the second half 2017, he was Managing Director for UK & Ireland and Management Centre European Agents. Prior to this he held various roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets. He is a member of Risk Committee.
Mr Duncan Patrick Cornish Chief Financial OfficerCompany Secretary Feb 2019
-
Mr Derek Thomson Chief Executive Officer Aug 2019
-
Derek Thomson Chief Executive Officer
-
Duncan Patrick Cornish Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Levenson Investments Pty Ltd <Levenson Investment A/C> 109,315,332 5.55%
First Cape Management Pty Ltd 55,346,154 2.81%
Marcolongo Nominees Pty Ltd <Marcolongo Super Fund A/C> 53,439,928 2.71%
Addison Lake Quality Hire Pty Limited 33,048,603 1.68%
Fossil Super Pty Ltd <Fossil Fund A/C> 32,459,231 1.65%
Jackjen Pty Ltd <J A Hamilton Super Fund A/C> 30,018,593 1.52%
Bond Street Custodians Limited <Antsm1 - D67076 A/C> 29,130,249 1.48%
Computer Visions Pty Ltd <Visionary Invests S/F A/C> 22,132,994 1.12%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient DRP> 21,599,216 1.10%
Mr Derek Thomson 21,580,554 1.10%
Marcolongo Nominees Pty Ltd <Marcolongo Family A/C> 20,134,578 1.02%
Mrs Mary Curtis 18,120,900 0.92%
Mr Peter Frederick Kemmis 17,198,314 0.87%
Citicorp Nominees Pty Limited 17,083,422 0.87%
Awo & Cao Investments Pty Ltd <Awo & Cao Family S/F A/C> 15,983,571 0.81%
Stydon Capital Pty Ltd 15,536,780 0.79%
Terry & Linden Deavin Super Pty Ltd <T & L Deavin Sf A/C> 14,600,000 0.74%
Austcorp No 190 Pty Ltd 14,381,945 0.73%
Mr Anthony William Olding & Mrs Caroline Anne Olding 14,091,375 0.72%
Mr Philip Michael Deavin & Mrs Chimene Maree Deavin 13,260,000 0.67%

Profile

since

Note